ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2013

BIIB059, a Monoclonal Antibody Targeting BDCA2, Shows Evidence of Biological Activity and Early Clinical Proof of Concept in Subjects with Active Cutaneous SLE

Richard Furie1, Victoria P. Werth2, Joseph Merola3, Wenting Wang4, Dania Rabah4, Catherine Barbey4, Cynthia Carrillo-Infante4, Taylor Reynolds4, Lauren Stevenson4, David Martin4 and Nathalie Franchimont4, 1Division of Rheumatology, Northwell Health, Great Neck, NY, 2Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, PA, 3Harvard Medical School, Boston, MA, 4Biogen, Cambridge, MA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Interferons and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 14, 2016

Session Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment III: Novel and Current Therapies

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:  Type I interferons (IFN-I) are implicated in the pathogenesis of systemic lupus erythematosus (SLE). BDCA2 is a plasmacytoid dendritic cell (pDC)-specific receptor that, upon engagement, inhibits the production of IFN-I and other inflammatory mediators produced by human pDCs. Targeting BDCA2, therefore, represents an attractive therapeutic strategy for inhibiting pDC-driven inflammation that is such a prominent feature of SLE. BIIB059 is an investigational humanized anti-BDCA2 monoclonal antibody. This first-in-patient study aimed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD) effects and clinical activity of BIIB059 in adult SLE patients with active cutaneous disease following administration of a single BIIB059 dose.

Methods:  A phase 1b randomized, double-blinded, placebo-controlled, multicenter clinical trial was conducted in 12 adult SLE subjects (meeting 1997 ACR criteria) with active cutaneous manifestations [including acute, sub-acute and/or chronic cutaneous forms of cutaneous lupus erythematosus (CLE)]. Subjects received a single IV administration of either BIIB059 20 mg/kg (n=8) or placebo (n=4). A panel of IFN-responsive genes (IRG) was assessed from whole blood by qPCR at baseline and several post-dose time points. Skin biopsies from active lesions were obtained and evaluated at baseline and week 4 for IFN-regulated proteins, including MxA using quantitative immunohistochemistry. CLE disease activity was determined using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI™), and safety data, including adverse events (AEs) and laboratory tests, were also collected.

Results:  Most SLE subjects had high IRG signatures in the blood and/or skin biopsies demonstrating features of inflammation consistent with active CLE, including elevated expression of MxA and other IFN-regulated proteins. A single dose of BIIB059 led to reversible inhibition of IRG in the blood. A marked decrease in skin expression of MxA at week 4 was observed in 5 of the 6 subjects treated with BIIB059 who had elevated MxA at baseline compared to less pronounced effects in the 4 placebo subjects (all with elevated baseline MxA). In addition, CLASI-activity at week 12 was also notably decreased in 6 of 8 BIIB059-treated subjects compared to the 4 placebo subjects (2/4 non-responders, 1/4 lost to follow-up and 1/4 treated with IV steroids for SLE flare). BIIB059 was generally well tolerated; the incidence of AEs was similar between BIIB059- and placebo-treated SLE subjects, and most AEs were mild or moderate in severity. There were no withdrawals due to AEs.

Conclusion:  A single dose of BIIB059 resulted in inhibition of the IRG in peripheral blood and MxA expression in lesional skin of SLE subjects, consistent with BIIB059’s proposed mechanism of action. The clinical and biomarker data together confirm the role of human pDCs in SLE skin pathology, and support further development of BIIB059 in SLE.


Disclosure: R. Furie, Biogen, 5; V. P. Werth, Biogen, 1,Biogen, 5; J. Merola, Biogen, 2,Biogen, Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Janssen, Mements, Mellincrode, 5,Abbvie, Eli Lilly, 8,Biogen, Pfizer, Boehringer Ingelheim, 9,Abbvie, 9; W. Wang, Biogen, 1,Biogen, 3; D. Rabah, Biogen, 1,Biogen, 3; C. Barbey, Biogen, 1,Biogen, 3; C. Carrillo-Infante, Biogen, 1,Biogen, 3; T. Reynolds, Biogen, 1,Biogen, 3; L. Stevenson, Biogen, 1,Biogen, 3; D. Martin, Biogen, 1,Biogen, 3; N. Franchimont, Biogen, 1,Biogen, 3.

To cite this abstract in AMA style:

Furie R, Werth VP, Merola J, Wang W, Rabah D, Barbey C, Carrillo-Infante C, Reynolds T, Stevenson L, Martin D, Franchimont N. BIIB059, a Monoclonal Antibody Targeting BDCA2, Shows Evidence of Biological Activity and Early Clinical Proof of Concept in Subjects with Active Cutaneous SLE [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/biib059-a-monoclonal-antibody-targeting-bdca2-shows-evidence-of-biological-activity-and-early-clinical-proof-of-concept-in-subjects-with-active-cutaneous-sle/. Accessed January 20, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/biib059-a-monoclonal-antibody-targeting-bdca2-shows-evidence-of-biological-activity-and-early-clinical-proof-of-concept-in-subjects-with-active-cutaneous-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.